This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Dechant, M. Articles by Valerius, T. Search for Related Content PubMed PubMed Citation Articles by Dechant, M. Articles by Valerius, T.

Complement-Dependent Tumor Cell Lysis Triggered by Combinations of Epidermal Growth Factor Receptor Antibodies

¹ Department of Nephrology and Hypertension, and ² Section of Stem Cell Transplantation and Immunotherapy, Christian-Albrechts-University, Kiel, Germany; ³ Genmab; and ⁴ Immunotherapy Laboratory, Department of Immunology, University Medical Centre Utrecht, Utrecht, the Netherlands

Requests for reprints: Thomas Valerius, Department of Nephrology and Hypertension, Christian-Albrechts-University, Schittenhelmstr. 12, 24105 Kiel, Germany. Phone: 49-431-597-1338; Fax: 49-431-597-1337; E-mail: valerius{at}nephro.uni-kiel.de.

Key Words: EGFR • complement killing • tumor therapy

Therapeutic monoclonal antibodies against the epidermal growth factor receptor (EGFR) have advanced the treatment of colon and head and neck cancer, and show great promise for the development of treatments for other solid cancers. Antibodies against EGFR have been shown to act via inhibition of receptor signaling and induction of antibody-dependent cellular cytoxicity. However, complement-dependent cytotoxicity, which is considered one of the most powerful cell killing mechanisms of antibodies, seems inactive for such antibodies. Here, we show a remarkable synergy for EGFR antibodies. Combinations of antibodies against EGFR were identified, which resulted in potent complement activation via the classic pathway and effective lysis of tumor cells. Studies on a large panel of antibodies indicated that the observed synergy is a general mechanism, which can be activated by combining human IgG1 antibodies recognizing different, nonoverlapping epitopes. Our findings show an unexpected quality of therapeutic EGFR antibodies, which may be exploited to develop novel and more effective treatments for solid cancers. [Cancer Res 2008;68(13):4998–5003]